On this page
GLP-1 medications copy a gut hormone that signals fullness, slows digestion, and quiets appetite, so you eat less without fighting constant hunger. In the STEP 1 trial, weekly semaglutide produced about 15% average body-weight loss over 68 weeks. They work best paired with changes to diet and activity.
The drugs behind the weight-loss headlines all share one trick. They imitate a hormone your own gut makes after a meal, the one that tells your brain you've had enough. Turn that signal up and keep it on, and most people simply want less food.
That's the short version. The longer one explains why these medications work where decades of diet pills mostly didn't, and why a clinician still reviews your history before anyone starts.
What GLP-1 medications are
GLP-1 stands for glucagon-like peptide-1, an incretin hormone your intestine releases within minutes of eating. It nudges the pancreas to release insulin, tamps down the hunger-driving hormone glucagon, and tells the brain you're satisfied. The catch is that natural GLP-1 breaks down in about two minutes. The medications are lab-made versions, called GLP-1 receptor agonists, engineered to bind the same receptors and last for days, which is why most are a once-weekly injection started low and stepped up over several weeks.
According to StatPearls, the receptor-agonist class was first developed for type 2 diabetes and later shown to drive substantial weight loss. The two used most for weight today are:
- Semaglutide, sold as Ozempic and Rybelsus for diabetes, and as Wegovy for weight management.
- Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight. It activates a second gut-hormone receptor, GIP, alongside GLP-1, which is why it's called a dual agonist. Our guide to tirzepatide covers what that second target adds.
How they lead to weight loss
Weight comes off because you take in fewer calories, and you do it without the white-knuckle hunger that sinks most diets. A GLP-1 works on several fronts at once. It slows how fast your stomach empties, so a normal meal keeps you full longer. It acts on appetite centers in the hypothalamus to lower hunger and quiet what many patients call "food noise," the background chatter about snacks and second helpings. And it boosts insulin only when blood sugar is high while suppressing glucagon, which steadies energy between meals.
Patients keep telling me the same thing: for the first time, food isn't running the show. That quiet is the medication doing its job, not willpower finally kicking in.
— John Venzor, DO
The numbers back up the feeling. In 2021, the STEP 1 trial published in the New England Journal of Medicine found that adults on weekly semaglutide lost a mean of 14.9% of their body weight at 68 weeks, against 2.4% on placebo. A year later, the SURMOUNT-1 trial reported that tirzepatide's highest dose produced about 20.9% average weight loss over 72 weeks. Older weight-loss drugs rarely cleared 5% to 10%, so this was a real step up in what medication alone can do.
Where these drugs came from
None of this started as a weight-loss project. GLP-1 receptor agonists were built to treat type 2 diabetes, where they lower blood sugar without much risk of dangerous lows. The weight loss showed up as a side effect striking enough that drugmakers ran dedicated obesity trials. The U.S. Food and Drug Administration approved semaglutide for chronic weight management as Wegovy in 2021, and tirzepatide followed as Zepbound in late 2023.
That history matters for two reasons. First, these molecules have a long safety track record from diabetes use, not just a few years of weight-loss data. Second, the same active ingredient can wear different brand names at different doses, which is why Ozempic and Wegovy are both semaglutide. If you want the brand-by-brand breakdown, the semaglutide guide sorts it out.
What they can and can't do
A GLP-1 is a tool, not a cure, and it works alongside food and movement rather than replacing them. The trials that produced those big numbers all paired the drug with lifestyle counseling. The honest limit is what happens when you stop: in a follow-up to the STEP 1 trial, participants regained roughly two-thirds of their lost weight within a year of coming off semaglutide. Obesity behaves like a chronic condition, and for many people the medication is something they stay on, much like blood-pressure treatment.
These drugs also aren't for everyone, and a few histories rule them out entirely. That's the part worth slowing down on before you start.
A GLP-1 is not appropriate if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), or if you're pregnant or breastfeeding. A history of pancreatitis also needs a closer look. This is exactly why a clinician reviews your full medical history before prescribing, rather than handing the same plan to everyone.
If side effects are your main worry, most are digestive and tend to ease as the dose climbs slowly. Our guide on GLP-1 side effects walks through what's common, what's rare, and when to call someone.